通心络胶囊联合华法林治疗心房纤颤的临床观察  

Clinical Observation of Tongxinluo Capsule Combined with Warfarin to Cure atrial FibrillatioN

作　　者：杨叶[1] 

机构地区：[1]包头医学院第一附属医院,内蒙古包头014010

出　　处：《中国伤残医学》2015年第1期8-9,共2页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的：探讨通心络胶囊对华法林治疗心房纤颤患者抗凝效果的影响。方法：选择长期服用华法林的心房纤颤患者58例，持续每天口服华法林抗凝治疗的29例作为对照组，在常规使用华法林基础上，加服通心络胶囊的29例作为观察组。应用国际标准化比值（ INR）监测患者治疗后凝血功能的变化。结果：观察组患者加服通心络胶囊5天后开始INR显著增高，并可明显减少华法林用量，2组比较差异有统计学意义（P＜0．05）。同时，观察组共发生5例轻微出血（牙龈／鼻腔出血、皮肤瘀斑）。结论：通心络胶囊可明显增强华法林抗凝作用，但增加患者出血的风险。Objective：To investigate tongxinluo capsule for the effect of anticoagulant effect using warfarin therapy in patients with atri-al fibrillation.Methods：Selecting long-term use of warfarin in patients with atrial fibrillation 58 cases, 29 cases with Continue daily oral warfarin anticoagulation as control group, on the basis of routine use of warfarin, 29 cases with adding tongxinluo capsule as observation group.International standardization ratio （ INR） monitoring in patients with the change of the blood coagulation function after treatment was applicated.Results：Observation group of patients add taking tongxinluo capsule after 5d, INR significantly higher, and can signifi-cantly reduce the dosage of warfarin, differences between the two groups have statistical significance （P〈0.05）.At the same time, the observation group has 5 cases occurring slight bleeding （ gum/nasal bleeding, skin ecchymosis） .Conclusion：Tongxinluo capsule can ob-viously enhance warfarin anticoagulation, but increase the risk of hemorrhage patients.

关 键 词：心房纤颤 通心络胶囊 华法林 国际标准化比值 

分 类 号：R541.7[医药卫生—心血管疾病]